{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:37:49Z","timestamp":1775083069179,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    We present the first metastatic castration-resistant prostate cancer (mCRPC) patient, heavily pretreated with multiple systemic and radioligand therapies, who received [\n                    <jats:sup>212<\/jats:sup>\n                    Pb]Pb-PSMA radioligand therapy (PRLT) combined with the metabotropic glutamate receptor (mGluR)-inhibitor Riluzole due to disease progression. This novel combination, aimed at targeting glutamine addiction in prostate cancer and exploiting radio-sensitization, was well tolerated leading to partial remission of the disease, decrease in PSA values, and stability of symptoms. This represents the first-in-human clinical application of [\n                    <jats:sup>212<\/jats:sup>\n                    Pb]Pb-PSMA PRLT combined with mGluR inhibition in mCRPC, representing a promising therapeutic strategy for advanced, treatment-refractory, progressing patients, supported by molecular imaging and clinical benefit.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006222","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:00:52Z","timestamp":1775077252000},"page":"e346-e347","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["First-in-Human Combination of Lead-212\u2013Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8404-8206","authenticated-orcid":false,"given":"Elisabetta","family":"Perrone","sequence":"first","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"},{"name":"Nuclear Medicine Unit, Department of Diagnostic Imaging and Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Greifenstein","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kriti","family":"Ghai","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph Markus","family":"Wirtz","sequence":"additional","affiliation":[{"name":"STRATIFYER Molecular Pathology GmbH, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard Paul","family":"Baum","sequence":"additional","affiliation":[{"name":"CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"R1-20260401","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2967\/jnumed.123.267189","article-title":"First-in-human 212Pb-PSMA-targeted \u03b1-therapy SPECT\/CT imaging in a patient with metastatic castration-resistant prostate cancer","volume":"65","author":"Griffiths","year":"2024","journal-title":"J Nucl Med"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2967\/jnumed.124.269299","article-title":"First-in-human phase 0 study of AB001, a prostate-specific membrane antigen-targeted 212Pb Radioligand, in patients with metastatic castration-resistant prostate cancer","volume":"66","author":"Berner","year":"2025","journal-title":"J Nucl Med"},{"key":"R3-20260401","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"DeBerardinis","year":"2008","journal-title":"Cell Metab"},{"key":"R4-20260401","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.124.3215.269","article-title":"On respiratory impairment in cancer cells","volume":"124","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","article-title":"Glutamine addiction: a new therapeutic target in cancer","volume":"35","author":"Wise","year":"2010","journal-title":"Trends Biochem Sci"},{"key":"R6-20260401","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R7-20260401","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.3390\/cells11182857","article-title":"Implications of a neuronal receptor family, metabotropic glutamate receptors, in cancer development and progression","volume":"11","author":"Eddy","year":"2022","journal-title":"Cells"},{"key":"R8-20260401","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1084\/jem.20171052","article-title":"Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors","volume":"215","author":"Kaittanis","year":"2018","journal-title":"J Exp Med"},{"key":"R9-20260401","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1158\/0008-5472.CAN-18-1500","article-title":"Concurrent targeting of glutaminolysis and metabotropic glutamate receptor 1 (GRM1) reduces glutamate bioavailability in GRM1+ melanoma","volume":"79","author":"Shah","year":"2019","journal-title":"Cancer Res"},{"key":"R10-20260401","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000369707","article-title":"Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K\/Akt\/mTOR pathway","volume":"35","author":"Zhang","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"44639","DOI":"10.18632\/oncotarget.17961","article-title":"Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells","volume":"8","author":"Dolfi","year":"2017","journal-title":"Oncotarget"},{"key":"R12-20260401","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-24-3964","article-title":"Riluzole in combination with mFOLFOX6 and bevacizumab in treating patients with metastatic colorectal cancer: a phase 1 clinical trial","volume":"31","author":"Li","year":"2025","journal-title":"Clin Cancer Res"},{"key":"R13-20260401","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1158\/1078-0432.CCR-12-1308","article-title":"Serum glutamate levels correlate with Gleason Score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells","volume":"18","author":"Koochekpour","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R14-20260401","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41388-024-03059-4","article-title":"Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer","volume":"43","author":"Beier","year":"2024","journal-title":"Oncogene"},{"key":"R15-20260401","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/ijo.2021.5275","article-title":"Riluzole: a neuroprotective drug with potential as a novel anti-cancer agent (Review)","volume":"59","author":"Blyufer","year":"2021","journal-title":"Int J Oncol"},{"key":"R16-20260401","first-page":"2195","article-title":"Riluzole induces apoptotic cell death in human prostate cancer cells via endoplasmic reticulum stress","volume":"29","author":"Akamatsu","year":"2009","journal-title":"Anticancer Res"},{"key":"R17-20260401","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.urolonc.2011.08.002","article-title":"Application of metabolomics to prostate cancer","volume":"29","author":"Trock","year":"2011","journal-title":"Urol Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:00:54Z","timestamp":1775077254000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006222","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"2025-07-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}